NCT06150742 Nafamostat Efficacy in Phase 3 Registrational CRRT Study
| NCT ID | NCT06150742 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Talphera, Inc |
| Condition | Acute Kidney Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-08-15 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2024-08-15 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.
Eligibility Criteria
Inclusion Criteria: * Patients requiring CRRT or undergoing CRRT initiated within the prior 48 hours * Patients who cannot tolerate heparin or are at high risk of bleeding Exclusion Criteria: * Patients weighing less than 50 kg * Patients receiving systemic anticoagulation * Patients with active bleeding
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06150742 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06150742 currently recruiting?
Yes, NCT06150742 is actively recruiting participants. Contact the research team at nazneen.patel@clinchoice.com for enrollment information.
Where is the NCT06150742 trial being conducted?
This trial is being conducted at Los Angeles, United States, Orlando, United States, Detroit, United States, Albuquerque, United States and 6 additional locations.
Who is sponsoring the NCT06150742 clinical trial?
NCT06150742 is sponsored by Talphera, Inc. The trial plans to enroll 70 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.